AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23510154 — intervention group
Group type: EXPERIMENTAL
Intervention: multicomponent lifestyle intervention (plain milk and enriched milk)
Number of subjects: 108
Study 23510154 — intervention group
Group type: COMPARATOR
Intervention: usual diet (control group)
Number of subjects: 108
Study 22161540 — intervention group
Group type: EXPERIMENTAL
Intervention: ColoPlus® (50 g twice a day for 4 weeks)
Number of subjects: 87
Study 22161540 — intervention group
Group type: COMPARATOR
Intervention: Standard anti-diarrhea treatment alone
Number of subjects: 87
Study 19244262 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigileo-FloTrac™ system version 1.07
Number of subjects: 60
Study 19244262 — intervention group
Group type: COMPARATOR
Intervention: Vigileo-FloTrac™ system version 1.03
Number of subjects: 60
Study 17115349 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart (BIAsp)
Number of subjects: 394
Study 17115349 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart (IAsp) + human isophane insulin (NPH)
Number of subjects: 394
Study 17115349 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp
Number of subjects: 394
Study 17115349 — intervention group
Group type: COMPARATOR
Intervention: IAsp + NPH
Number of subjects: 394
Study 14964505 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental physical training program (PTP)
Number of subjects: 307
Study 14964505 — intervention group
Group type: COMPARATOR
Intervention: Official physical training program (PTP)
Number of subjects: 307
Study 11530155 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally-based health promotion programme introduced in 1981, details on dosage and duration not applicable.
Number of subjects: 0
Study 11530155 — intervention group
Group type: COMPARATOR
Intervention: Control areas without the health promotion programme.
Number of subjects: 0
Study 9145878 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 2 mg/kg
Number of subjects: 11
Study 9145878 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin 7 mg/kg
Number of subjects: 11
Study 8198053 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (900 mg d-alpha-tocopherol/d)
Number of subjects: 20
Study 8198053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30194502 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination HIV-prevention and microfinance intervention including HIV-risk reduction, financial-literacy training, vocational training, and a matched-savings program.
Number of subjects: 0
Study 30236380 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy with vigabatrin
Number of subjects: 377
Study 30236380 — intervention group
Group type: COMPARATOR
Intervention: Hormonal therapy alone
Number of subjects: 377
Study 30236380 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial control of spasms between days 14 and 42 of treatment
Number of subjects: 377
Study 30236380 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing lead-time to treatment
Number of subjects: 377
Study 27772740 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release fampridine (10mg, twice daily)
Number of subjects: 68
Study 24474383 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 291
Study 24474383 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 10 mg/kg
Number of subjects: 291
Study 23306418 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 (200 mg daily)
Number of subjects: 20
Study 23306418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 20881069 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg ZnO/d for 5 d/wk)
Number of subjects: 674
Study 20881069 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 mg glucose)
Number of subjects: 674
Study 20881069 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 674
Study 18594845 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-FU/oxaliplatin-based chemotherapy (FUFOX vs. CAPOX)
Number of subjects: 108
Study 16762794 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 6800
Study 16762794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6800
Study 12846707 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine 0.1 mg.kg‐1 postinduction (EP group, n = 25)
Number of subjects: 50
Study 12846707 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine infusion at 0.02 mg.kg‐1.h‐1 following 0.05 mg.kg‐1 bolus (INF group, n = 25)
Number of subjects: 50
Study 12846707 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 50
Study 11103759 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine fumarate (Seroquel)
Number of subjects: 2
Study 11103759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 8840904 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg naltrexone
Number of subjects: 16
Study 8840904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8840904 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 16
Study 1539006 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement of oncology clinical nurse specialists in research
Number of subjects: 0
Study 6088819 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg capsules orally five times daily for ten days
Number of subjects: 150
Study 6088819 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules orally five times daily for ten days
Number of subjects: 150
Study 6088819 — intervention group
Group type: EXPERIMENTAL
Intervention: Acyclovir 200 mg capsules
Number of subjects: 150
Study 6088819 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 150
Study 6088819 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir and Placebo
Number of subjects: 150
Study 31527894 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 0
Study 29018956 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic training using virtual reality (VR)
Number of subjects: 90
Study 29018956 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematic training using laser
Number of subjects: 90
Study 29018956 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 27503039 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 Hz frequency of latency
Number of subjects: 120
Study 27503039 — intervention group
Group type: COMPARATOR
Intervention: 1.0 Hz frequency of latency
Number of subjects: 120
Study 24549600 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorexia nervosa group (n=86)
Number of subjects: 107
Study 24549600 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (n=21)
Number of subjects: 107
Study 23147696 — intervention group
Group type: EXPERIMENTAL
Intervention: JTT-751 (1.5 g/day)
Number of subjects: 192
Study 23147696 — intervention group
Group type: EXPERIMENTAL
Intervention: JTT-751 (3 g/day)
Number of subjects: 192
Study 23147696 — intervention group
Group type: EXPERIMENTAL
Intervention: JTT-751 (6 g/day)
Number of subjects: 192
Study 23147696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 20832440 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of weight-related cues (body-weight scale) in Study 1
Number of subjects: 0
Study 20832440 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of weight-related cues (weight-related verbal statement) in Study 2
Number of subjects: 0
Study 20832440 — intervention group
Group type: COMPARATOR
Intervention: No weight-related cues in both studies
Number of subjects: 0
Study 17526169 — intervention group
Group type: EXPERIMENTAL
Intervention: Liuwei Dihuang Soft Capsule (LDSC) plus Ginkgo Leaf Tablet (GLT)
Number of subjects: 40
Study 17526169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15321408 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting posture
Number of subjects: 93
Study 15321408 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hip‐flexed left lateral position
Number of subjects: 93
Study 15321408 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hip‐flexed right lateral position
Number of subjects: 93
Study 15321408 — intervention group
Group type: COMPARATOR
Intervention: Supine 30 degrees lateral tilt
Number of subjects: 93
Study 12521415 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient cervical cerclage
Number of subjects: 50
Study 12521415 — intervention group
Group type: COMPARATOR
Intervention: Inpatient cervical cerclage
Number of subjects: 50
Study 9437777 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin (5.1%, 5/98 positive for C. trachomatis)
Number of subjects: 196
Study 9437777 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose doxycycline (4.1%, 4/98 positive for C. trachomatis)
Number of subjects: 196
Study 9437777 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose therapy compliance (94.5% among 73 women)
Number of subjects: 196
Study 9437777 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for persistence or recurrence
Number of subjects: 196
Study 8591098 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast system response time
Number of subjects: 12
Study 8591098 — intervention group
Group type: COMPARATOR
Intervention: Slow system response time
Number of subjects: 12
Study 8591098 — intervention group
Group type: EXPERIMENTAL
Intervention: Delete input numerals
Number of subjects: 12
Study 8591098 — intervention group
Group type: COMPARATOR
Intervention: Do not delete input numerals
Number of subjects: 12
Study 8591098 — intervention group
Group type: EXPERIMENTAL
Intervention: Button flashes after input
Number of subjects: 12
Study 8591098 — intervention group
Group type: COMPARATOR
Intervention: No button flashes after input
Number of subjects: 12
Study 8591098 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaining time displayed
Number of subjects: 12
Study 8591098 — intervention group
Group type: COMPARATOR
Intervention: Remaining time not displayed
Number of subjects: 12
Study 2473403 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide or flecainide
Number of subjects: 2309
Study 2473403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2309
Study 604922 — intervention group
Group type: EXPERIMENTAL
Intervention: Social reinforcement procedure for visual attention
Number of subjects: 16
Study 604922 — intervention group
Group type: COMPARATOR
Intervention: Control group (no social reinforcement)
Number of subjects: 16
Study 31318832 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate administration
Number of subjects: 0
Study 31419610 — intervention group
Group type: EXPERIMENTAL
Intervention: Moment‐by‐Moment in Women's Recovery (MMWR)
Number of subjects: 200
Study 31419610 — intervention group
Group type: COMPARATOR
Intervention: Control group (time‐matched psychoeducation)
Number of subjects: 200
Study 28640214 — intervention group
Group type: EXPERIMENTAL
Intervention: Hayward kiwifruit (with actinidin)
Number of subjects: 10
Study 28640214 — intervention group
Group type: COMPARATOR
Intervention: Hort16A kiwifruit (without actinidin)
Number of subjects: 10
Study 28640214 — intervention group
Group type: EXPERIMENTAL
Intervention: Both kiwifruit types
Number of subjects: 10
Study 26075538 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone replacement therapy (TRT) - 250 mg of testosterone enanthate as an intramuscular injection every 4 weeks for 6 months
Number of subjects: 64
Study 26075538 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention details provided)
Number of subjects: 64
Study 23815743 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings clusters identified through Latent Class Analysis
Number of subjects: 631
Study 23815743 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent Class Analysis
Number of subjects: 631
Study 23815743 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI findings
Number of subjects: 631
Study 21959095 — intervention group
Group type: EXPERIMENTAL
Intervention: SEEK model training for pediatric residents
Number of subjects: 95
Study 21959095 — intervention group
Group type: COMPARATOR
Intervention: Standard care from control residents
Number of subjects: 95
Study 19803628 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Concerta)
Number of subjects: 49
Study 19803628 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 16446330 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Carboplatin (TC)
Number of subjects: 798
Study 12919083 — intervention group
Group type: EXPERIMENTAL
Intervention: Large database analysis in renal transplantation
Number of subjects: 0
Study 12919083 — intervention group
Group type: COMPARATOR
Intervention: Single center and randomized prospective studies
Number of subjects: 0
Study 12919083 — intervention group
Group type: COMPARATOR
Intervention: Statistical considerations
Number of subjects: 0
Study 11019835 — intervention group
Group type: EXPERIMENTAL
Intervention: SCF plus filgrastim (20 microg/kg/day + 10 microg/kg/day)
Number of subjects: 102
Study 11019835 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim alone (10 microg/kg/day)
Number of subjects: 102
Study 8736296 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-articular reconstruction
Number of subjects: 0
Study 8736296 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular reconstruction
Number of subjects: 0
Study 1539754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150 micrograms/kg body weight) given once every three months for four, eight, or eleven doses
Number of subjects: 0
Study 1539754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (150 micrograms/kg body weight) given once every three months
Number of subjects: 0
Study 1539754 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated persons)
Number of subjects: 0
Study 2951792 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol
Number of subjects: 10
Study 2951792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 10
Study 2951792 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of fenoterol and ipratropium bromide
Number of subjects: 10
Study 31705983 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective TEVAR for DTAA
Number of subjects: 1784
Study 31095126 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric interval hypoxic therapy and enteral oxygen therapy
Number of subjects: 230
Study 31095126 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 230
Study 28419387 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 169
Study 25809173 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferiprone
Number of subjects: 0
Study 25809173 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 0
Study 22939108 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 20 mg/kg
Number of subjects: 44
Study 22939108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 21228265 — intervention group
Group type: EXPERIMENTAL
Intervention: High-salt meal (HSM; 65 mmol Na)
Number of subjects: 16
Study 21228265 — intervention group
Group type: COMPARATOR
Intervention: Low-salt meal (LSM; 5 mmol Na)
Number of subjects: 16
Study 18602726 — intervention group
Group type: EXPERIMENTAL
Intervention: TIV from multi‐dose vials with thimerosal
Number of subjects: 100
Study 18602726 — intervention group
Group type: EXPERIMENTAL
Intervention: TIV from pre‐filled syringes without thimerosal
Number of subjects: 100
Study 18602726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 17041825 — intervention group
Group type: EXPERIMENTAL
Intervention: Constraint-Induced Movement Therapy (CIMT)
Number of subjects: 39
Study 17041825 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of movement on the WMFT (functional ability score)
Number of subjects: 39
Study 17041825 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of movement on the WMFT (timed score)
Number of subjects: 39
Study 12534514 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Ultrapulse CO2 laser and Q-switched alexandrite laser (QSAL)
Number of subjects: 6
Study 12534514 — intervention group
Group type: COMPARATOR
Intervention: Q-switched alexandrite laser (QSAL) alone
Number of subjects: 6
Study 15354456 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.42% fluoride gel
Number of subjects: 27
Study 15354456 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fluoride gel)
Number of subjects: 27
Study 9255720 — intervention group
Group type: EXPERIMENTAL
Intervention: NONMEM approach
Number of subjects: 14
Study 9255720 — intervention group
Group type: EXPERIMENTAL
Intervention: log-likelihood procedure
Number of subjects: 14
Study 9255720 — intervention group
Group type: COMPARATOR
Intervention: traditional NONMEM approach
Number of subjects: 14
Study 9255720 — intervention group
Group type: COMPARATOR
Intervention: standard approach
Number of subjects: 14
Study 9255720 — intervention group
Group type: COMPARATOR
Intervention: standard method
Number of subjects: 14
Study 9255720 — intervention group
Group type: EXPERIMENTAL
Intervention: NONMEM
Number of subjects: 14
Study 8497343 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) sequentially combined with 75 micrograms of levonorgestrel
Number of subjects: 3
Study 8497343 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) sequentially combined with 150 micrograms of desogestrel
Number of subjects: 3
Study 8497343 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) sequentially combined with 10 mg of medroxyprogesterone acetate
Number of subjects: 3
Study 3305088 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium salt supplementation
Number of subjects: 0
Study 3305088 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamterene (potassium blocking agent)
Number of subjects: 0
Study 29338855 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg twice daily vaginal Endometrin
Number of subjects: 645
Study 29338855 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg daily intramuscular P only
Number of subjects: 645
Study 29338855 — intervention group
Group type: COMPARATOR
Intervention: 200 mg twice daily Endometrin plus 50 mg intramuscular P every 3rd day
Number of subjects: 645
Study 26908758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole (750 mg) plus miconazole (200 mg) for 5 consecutive nights each month for 12 months
Number of subjects: 234
Study 26908758 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 consecutive nights each month for 12 months
Number of subjects: 234
Study 26908758 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal metronidazole plus miconazole
Number of subjects: 234
Study 24751822 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FCM) 1000 mg iron
Number of subjects: 290
Study 24751822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 290
Study 23412930 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg daily (n = 58)
Number of subjects: 115
Study 23412930 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 57)
Number of subjects: 115
Study 20810168 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted intervention
Number of subjects: 5500
Study 20810168 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention
Number of subjects: 5500
Study 20810168 — intervention group
Group type: COMPARATOR
Intervention: Control group (survey-only)
Number of subjects: 5500
Study 20810168 — intervention group
Group type: COMPARATOR
Intervention: Targeted intervention vs Control group
Number of subjects: 5500
Study 20810168 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention vs Targeted intervention
Number of subjects: 5500
Study 18440519 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant LH 75 IU/day
Number of subjects: 20
Study 18440519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 16834833 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine 6 mg
Number of subjects: 18
Study 16834833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 120 mg
Number of subjects: 18
Study 16834833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 12763318 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge-subtyping condition (neutral feature predicts stereotype-congruence)
Number of subjects: 0
Study 12763318 — intervention group
Group type: COMPARATOR
Intervention: Knowledge-standard condition (neutral feature uncorrelated with stereotype-congruence)
Number of subjects: 0
Study 12763318 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiment 2 (generalization of effects)
Number of subjects: 0
Study 10859708 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9543657 — intervention group
Group type: EXPERIMENTAL
Intervention: Families of patients with psychiatric disorders
Number of subjects: 353
Study 9543657 — intervention group
Group type: COMPARATOR
Intervention: Control group of nonclinical families
Number of subjects: 353
Study 8446720 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid tissue expansion (once a day, starting 1 week postoperatively, for 14 days)
Number of subjects: 50
Study 8446720 — intervention group
Group type: COMPARATOR
Intervention: Slow tissue expansion (once a week, starting after 2 weeks, for 41 days)
Number of subjects: 50
Study 8446720 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients (combined data)
Number of subjects: 50
Study 8446720 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid tissue expansion (once a day)
Number of subjects: 50
Study 8446720 — intervention group
Group type: COMPARATOR
Intervention: Slow tissue expansion (once a week)
Number of subjects: 50
Study 3446535 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT) following surgical peripheral iridectomy (PI) or laser iridotomy (LI)
Number of subjects: 52
Study 3446535 — intervention group
Group type: COMPARATOR
Intervention: No ALT treatment following PI or LI
Number of subjects: 52
Study 3446535 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridoplasty followed by ALT
Number of subjects: 52